26 September 2024
BSR is delighted to confirm our continued support for our PsA patient register with an extension through to September 2027 now finalised.
The Psoriatic Arthritis register, based at the University of Aberdeen, will now be able to continue it’s valuable work on behalf of the rheumatology community and with more therapies becoming available for PsA we feel there is real opportunity for growth with this study.
Gareth Jones, Chief Investigator on the BSR-PsA register adds;
“We’re delighted that the BSR’s support of the Psoriatic Arthritis Register will be extended until September 2027.
By increasing the duration of recruitment on the study we have an opportunity to provide a larger patient cohort and can capture patients commencing newly available and soon to be available therapies for PsA.
The ability to collect longer-term follow-up data from current participants will be of enormous benefit as well, allowing us to examine rarer outcome events in these patients and providing a richer, more valuable dataset for research purposes moving forward.”
More information on the PsA register and how to get involved can be found here